The Canadian Venous Thromboembolism Research Network is a pan-Canadian, patient-oriented research network dedicated to VTE.
Joined January 2016
- Tweets 3,204
- Following 953
- Followers 1,822
- Likes 2,205
908 Photos and videos
Join us for the final 2025–26 National #Thrombosis seminar: "Precision in DOAC reversal — a trainee-led UK network."
June 8, 12:00 ET | Featuring Dr Richard Buka !
Register to attend: buff.ly/FWlEuEc
#Anticoagulation #VTE #Research
3
345
CanVECTOR Network retweeted
Mar 31
The debate over DOAC selection just got clearer. 🔍
The #COBRRA trial provides a definitive head-to-head look at bleeding risks in #VTE. Tomorrow, we explore the findings!
Join the deep dive with @LanaCastellucci
Register to attend🔗 bit.ly/4thelZT
#Research
1
4
294
Susan Kahn is a leading voice in venous thrombosis & its long-term complications. Her work has helped shape patient care and clinical practice globally. Now honored with the 2026 ISTH Esteemed Career Award, she reflects on her career: isth.org/news/news.asp?id=72…
3
11
623
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary: nejm.org/doi/full/10.1056/NE…
19
63
12,211
CanVECTOR Network retweeted
Mar 12
Dans le cadre d’une étude menée par la Dre Lana Castellucci, deux types d’anticoagulants souvent utilisés pour traiter la thromboembolie veineuse ont été comparés. L’un de ces médicaments a pu diminuer de plus de 50 % les cas d’hémorragie.
cihr-irsc.gc.ca/f/54578.html…
ALT Dre Lana Castellucci
1
2
148
CanVECTOR Network retweeted
Mar 12
A study led by Dr. Lana Castellucci compared two types of anticoagulants commonly used to treat venous thromboembolism and showed that one of the medications reduced bleeding by more than 50%.
Learn more: cihr-irsc.gc.ca/e/54578.html…
#BloodClotAwarenessMonth
ALT Dr. Lana Castellucci
1
2
11
841
CanVECTOR Network retweeted
Mar 13
Groundbreaking research at The Ottawa Hospital ctvnews.ca/ottawa/video/2026…
1
1
9
3,326
CanVECTOR Network retweeted
Mar 12
🐍 COBRRA trial finds ↓ clinically relevant bleeding with apixaban vs. rivaroxaban during the first 3 months of treatment for acute VTE (RR 0.46, 95% CI 0.33–0.65)🩸
@uOttawaMed @OttawaHospital @CIHR_IRSC @INVENT_VTE
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: nejm.org/doi/full/10.1056/NE…
1
4
11
677
CanVECTOR Network retweeted
Mar 12
Ottawa Hospital research finds ‘clear winner’ for safer blood clot treatment ctvnews.ca/ottawa/article/ot…
2
6
30
4,730
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: nejm.org/doi/full/10.1056/NE…
8
385
1,138
241,625
CanVECTOR Network retweeted
Feb 26
Excited to share this fantastic new tool from @ASH_hematology
trialmap.hematology.org/
TrialMap is the perfect resource for early-career clinician investigators. Guiding you from trial concept 💡 to practice-changing results 📄.
A must-bookmark if launching a clinical trial!
2
11
356
CanVECTOR Network retweeted
Feb 20
In ARTESiA:
Stroke ↓ 37%
Major bleeding ↑
Fatal & intracranial bleeding: similar
Understanding severity — not just frequency — changes the conversation.
New episode of CLOT Conversations: thrombosiscan.info/CLOT-Conv…
#Anticoagulation #AFib #Thrombosis @DebSiegal
3
5
297
CanVECTOR Network retweeted
Feb 17
Can we safely rule out #DVT using age-adjusted D-dimer cutoffs? 🩺
Join our 1st 2026 Global Thrombosis Seminar! Dr. Grégoire Le Gal discusses the #ADJUST-DVT study (recently in @JAMA_current).
🗓️ Feb 25 🕘 14:00 UTC
🔗Register: bit.ly/3ONxyTZ
#VTE #MedEd #Research
1
4
185
CanVECTOR Network retweeted
Feb 16
‼️So exciting to have one of my #BantingCanada postdoc projects, published last year in the #EuropeanHeartJournal, recognized among the Top 10 Research Papers of 2025 in the field of #CardioOncology 🙏🏼🎉
academic.oup.com/eurheartj/a…
2
13
665
📣 NEWS: The ISTH announces five global recipients of 2026 Esteemed Career Awards! This award honors leaders in thrombosis and hemostasis whose life-long achievements have shaped the field through scientific excellence.
Learn more: isth.org/news/news.asp?id=72…
6
17
1,098
Join us for our upcoming National #Thrombosis Seminar on "Periprocedural Anticoagulation Management for Central Line Insertion in Persons with Cancer."
Featuring: Dr. Jameel Abdulrehman - University of Toronto
📅 Feb 11 at 12:00 p.m. ET.
Register: buff.ly/HPVWh1d
1
4
250
Jan 21
📢 Funding & Training Opportunities
Applications are OPEN for the Fall 2025 #CanVECTOR competitions:
✅ Pilot Study Funding ✅ Research Start-Up Awards ✅ Fellowships
PLUS: The Dr. Jack Hirsh Fellowship via @HamHealthSci & @McMasterU!
🔗 buff.ly/eXiHZ2o
1
114
Jan 15
Join us today at 12pm ET for our next National Thrombosis Seminar on "Biomarkers & Genetics for the Prediction of #VTE & Clinically Relevant Bleeding in Cancer Patients" -
Featuring: Danielle Roy, PhD
Register: buff.ly/MzRb0MT
#Thrombosis #Research
1
73
CanVECTOR Network retweeted
Jan 14
🩺🧠 I will be chairing this Morning Report–style thrombosis cases, discussed live by an expert panel seeing the cases for the first time.
🎯 Perfect for thrombosis nerds
💻 Free & open to all. Register now! 👇
Hosted by @ThrombosisCan
🩸 #Thrombosis #MedEd
Jan 13
New CPD Webinar: Clinical Challenges in Thrombosis II
Live, unscripted cases. Real-time expert discussion.
March 3 | 7:00 PM ET
Register: thrombosiscan.info/ClinicalC…
4
12
1,136
CanVECTOR Network retweeted
Jan 13
New CPD Webinar: Clinical Challenges in Thrombosis II
Live, unscripted cases. Real-time expert discussion.
March 3 | 7:00 PM ET
Register: thrombosiscan.info/ClinicalC…
3
6
1,366